Nagasaka et al., Stereoselective Synthesis of Tilivalline, Tetrahedron Letters, vol. 30, No. 14, pp. 1871-1872, 1989.* |
Fukuyama et al., Total Synthesis of (+)-Porothramycin B, Tetrahedron Letters, vol. 34, No. 16, pp. 2577-2580, 1993.* |
Wilson et al., Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure, Tetrahedron Letters, vol. 36, No. 35, pp. 6333-6336, 1995.* |
Katritzky et al., Heterocyclic Chemistry, John Wiley & Sons, Inc., 1960, pp. 247-253.* |
Grant et al., Grant and Hackh's Chemical Dictionary, McGraw-Hill Book Company, 1987, p. 282.* |
Bundgaard, H., “Design and Application of Prodrugs”, 113-135, A Textbook of Drug Design and Development, eds Krogsgaard-Lassen, P., and Bundgaard, H., Harwood Academic Press (1991). |
Foloppe, M.P., et al., “DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazepine N10-C11 amidines” Eur. J. Med. Chem., 31, 407-410 (1996). |
Kamal, A., et al., “An Efficient Synthesis of Pyrrolo[2,1-c][1,4] Benzodiazepine Antibiotics via Reductive Cyclization,” Bioorg.Med.Chem.Ltrs, v.7, No. 14, 1825-1828 (1997). |
Kamal, A., et al. Synthesis of Pyrrolo [2,1-c][1,4]-Benzodiazepene Antibiotics: Oxidation of Cyclic Secondary Amine with TPAP, Tetrahedron, v. 53, No. 9. 3223-3230 (1997). |
Thurston, D.E., “Synthesis of Sequence-selective C8-linked Pyrrolo [2,1-c][1,4] Benzodiazepine DNA Interstrand Cross-linking Agent,” J. Org. Chem., 61, 8141-9147 (1996). |
Gregson, S. J. et al., “Synthesis of a novel C2/C2'-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity”, Chemical Communications, 797-798 (1999). |
Guiotto A. et al., “Synthesis of novel C7-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) via Pro-N10-troc protection and suzuki coupling”, Bioorganinc & Medicinal Chemistry Letters, vol. 8, No. 21, 3017-3018 (1998). |
Leimgruber et al., Am. Chem. Soc., 87, 5793-5795 (1965). |
Leimgruber et al., J. Am. Chem. Soc., 87, 5791-5793 (1965). |
Thurston et al., Chem. Rev., 1994, 433-465 (1994). |
Hochlowski et al., J. Antibiotics, 40, 145-148 (1987). |
Konishi et al., J. Antibiotics, 37, 200-206 (1984). |
Thurston et al., Chem. Brit., 26, 767-772 (1990). |
Bose et al., Tetrahedron, 48, 751-758 (1992). |
Kunimoto et al., J. Antibiotics, 33, 665-667 (1980). |
Takeuchi et al., J. Antibiotics, 29, 93-96 (1976). |
Tsunakawa, et al., J. Antibiotics, 41, 1366-1373 (1988). |
Shimizu et al., J. Antiobiotics, 35, 972-978 (1982). |
Langley and Thurston, , J. Org. Chem., 52, 91-97 (1987). |
Hara et al., J. Antibiotics, 41, 702,704 (1988). |
Itoh et al., J. Antibiotics, 41, 1281-1284 (1988). |
Leber et al., J. Am. Chem. Soc., 110, 2992-2993 (1988). |
Arima et al., J. Antibiotics, 25, 437-444 (1972). |
Kohn, Antibiotics III, Springer-Verlag, NY, 3-11 (1975). |
Hurley and Needham-VanDevanter, Acc. Chem. Res., 19, 230-237 (1986). |
Althuis, T. H. and Hess, H. J “Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat”, J. Medicinal Chem., 20(1), 146-266 (1977). |
Nagasaka, T. et al.,. “Stereoselective synthesis of tilivalline”, Journal of Organic Chemistry, vol. 36, No. 20, 6797-6801 (1998). |
Baraldi, P. G. et al., “Design, synthesis and biological activity of a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid”, Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 21, 3019-3024 (1998). |
Huber et al., Proc. Natl. Acad. Sci. USA, 88, 8039 (1991). |
Morgan & French, Annu. Rev. Biochem., 62, 191 (1993). |
Lewis et al., Carcinogenesis, 9, 1283-1287 (1988). |
Kuzmich et al., Journal of Biochemistry, 281, 219-244 (1992). |
Culver et al., Science, 256, 1550-1552 (1992). |
Englehardt et al., Nature Genetics, 4, 27-34 (1993). |
Ram, Z. et al., Cancer Research, 53, 83-88 (1993). |
Dalton & Treisman, Cell, 68, 597-612 (1992). |
Mizushima and Nagata, Nucl. Acids Res., 18, 5322 (1990). |
Tew et al., Glutathione-S-tranferase and anti-cancer drug resistance in Mechanism of Drug Resistance in Neoplastic Cells, Wooley, P.V., Tew K. D., Eds, Academic Press: Oralndo, FL 141-159 (1987). |
Satyam et al.,Med. Chem., 39, 1736-1747 (1996). |
Nicolaou et al. Science, 256, 1172-1178 (1992). |
Jungheim, L. N. and Shepherd, T. A., “Design of Antitumor Prodrugs: Substrates for Antibody Targeted Enzymes”, Am. Chem. Soc. Chem. Rev., 96: 6, 1553-1566 (1994). |
Pillai, R. V. N., “Photoremovable protecting groups in organic chemistry”, Synthesis, 1-26 (1980). |
Bayley, H., Gasparro, F., and Edelson, R., “Photoreactivatible drugs”, TIPS, 8, 138-143 (1987). |
Star, W. M., “Light delivery and light dosimetry for photodynamic therapy”, Laser in Medical Science, 5m 107-113 (1990). |
Carruth, J. A. S.,“Clinical applications for photodynamic therapy”, J. Photochem Photobiol., 9, 396-397 (1991). |
Kennedy, J. C. and Pottier, R. H., “Endogenous protoporphyrin IX, a clinical useful photosensitiser for photodynamic therapy”, J. Photochem Photobiol, 14, 275-292 (1992). |
Regula, J., Mac Roberts, A. J., Gorchein, A., Buonaccorsi, Thorpe, S. M., Spencer, G. M., Hartfield, A. R. W. and Brown, S. G. “Photosensitisation and photodynamic therapy of oesophageal, duodenal and colorectal tumours using 5-aminoleavulic acid induced protoporphyrin IX-a pilot study”, Gut, 36, 67-75 (1995). |
Bagshawe et al., Antibody, Immunoconjugates, and Radiopharmaceuticals, 4, 915-922 (1991). |
Monks, A. et al., Journal of National Cancer Institute, 83, 757 (1991). |
Thurston, D.E., “Advances in the study of Pyrrolo[2,1-c][4,1] benzodiazepine (PBD) Antitumour Antibiotics”, Molecular Aspects of Anticancer Drug-DNA interactions, Neidle, S., Waring, M.J. eds., Macmillan Press Ltd., 1: 54-88 (1993). |
Sagnou, M.J. et al., Bioorganic & Medicinal Chemistry Letters, 10, 2083-2086 (2000). |
Baraldi, P.G., et al., “Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers”, J. Med. Chem., 42: 5131-5141 (1999). |